SNS-314 mesylate

SKU: orb1305262

Description

SNS-314 Mesylate is a potent and selective pan-Aurora kinase inhibitor, demonstrating high specificity for Aurora A, B, and C with IC50 values of 9, 31, and 3 nM, respectively. It has shown reduced activity against several off-target kinases, including TrkA/B and Fms. This compound is a valuable chemical probe for investigating Aurora kinase biology in cellular and in vivo cancer models.

Research Area

Cell Biology, Epigenetics & Chromatin

Key Properties

• CAS Number: 1146618-41-8
• MW: 527.04
• Purity: >98%
• Formula: C₁₈H₁₅ClN₆OS₂·CH₃SO₃H
• SMILES: CS(O)(=O)=O.Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1
• Target: Kinase
• Solubility: Soluble in DMSO (up to at least 25 mg/ml)

Bioactivity

• Target IC50:
  Aurora A:9 nM|Aurora B:31 nM|Aurora C:3 nM
• In Vivo:
  Continuous treatment with SNS-314 in combination with gemcitabine, carboplatin, doxorubicin, fluorouracil, and SN-38 enhances antiproliferative effects. Synergistic effects are observed when SNS-314 is used together with gemcitabine, docetaxel, or vincristine. SNS-314 exhibits significant inhibitory activity against tumor cell lines (IC50: 1.8-24 nM), independent of the relative protein levels of Aurora-A or Aurora-B.
  Read more...
• In Vitro:
  In HCT116 colon xenograft models, SNS-314 exhibits significant and sustained anticancer effects. Additionally, in xenograft models of human breast cancer, prostate cancer, lung cancer (H1299 and Calu-6), ovarian cancer, and malignant melanoma, SNS-314 (170 mg/kg) demonstrates a tumor growth inhibition rate of 54-91%.
  Read more...
• Cell Research:
  Viability is measured using the CellTiter-Blue cell viability assay. Cells are treated as described above, although with a 5-day incubation period. Cytotoxicity is determined by measuring intracellular ATP using the CellTiter-Glo Luminescence Cell Viability Assay. Cells are seeded in white 96-well tissue culture plates at a density of 1.5-2 × 103 cells/well, and a serial dilution of SNS-314 is dosed in combination with fixed concentrations of either docetaxel or vincristine for a total of 72 hours. Viability is determined as the ratio between the ATP in treated cells versus control cells. Apoptosis is measured using the caspase-Glo 3/7 system. Cells are plated in white 96-well plates as described above and treated first with SNS-314 for 24 hours, washed with 200 μL of 1× PBS, and fresh medium is added with the second agent for 24 hours.(Only for Reference)
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

PC-3, HT29, H-1299, A2780, AuroraKinase, Aurora Kinase, Aurora C, Aurora B, Aurora A, ovarian cancer cell, SNS-314, SNS314 Mesylate, SNS-314 Mesylate, SNS 314 Mesylate

Compound Identifiers

PubChem CID

24995523